Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
JPMorgan Chase & Co. ( JPM - Analyst Report ) is set to drop overdraft fees on debit card transactions of $5 or less, effective next month. Currently, the company charges $34 per purchase, irrespective of the size of transaction. With implementation of this change, customers will be relieved of paying fees on smaller transactions.
The decision to scrap fees stems from the lawsuit settlement that cost JPMorgan $110 million in damages. Infuriated customers, who condemned the bank’s dubious ways of overcharging overdraft fees, had filed this class action lawsuit. The bank’s decision to nullify overdraft fees seems to be a measure to work upon its dented goodwill.
JPMorgan and several other major banks like Commerce Bancshares Inc ( CBSH - Analyst Report ) and Bank of America Corporation ( BAC - Analyst Report ) were accused of reordering transactions from largest to the smallest, causing the balances to deplete faster. This made customers vulnerable to excessive fees. It caused a nationwide uproar, and the customers filed various lawsuits demanding compensation. It also necessitated regulatory authorities to take measures against banks’ unwarranted activities.
Earlier this year, JPMorgan had reduced its overdraft protection transfer fee from $12 to $10. Also, the fee charged for stop payment was lowered to $30 from $34. In addition to this, if stop-payment is appealed via phone or online, the bank will charge $25 instead of $27. All of these measures have placed JPMorgan apart from the rest of the banking giants, which have resorted to fee hikes.
Some banks, like Fifth Third Bancorp ( FITB - Analyst Report ) and U.S. Bancorp ( USB - Analyst Report ) , are set to increase the overdraft fees considerably. Wells Fargo & Company ( WFC - Analyst Report ) has introduced a monthly checking fee of $7. According to a survey conducted by Consumer Federation of America, many more banking institutions are about to follow this trend. This will come as a major setback for customers, who are reeling under high fees.
Conclusion
Of late, JPMorgan has been in the news for the all wrong reasons. Lawsuits, losses and the recent downgrade of credit rating by Moody’s all dealt blows to the banking giant. Therefore, the action to reduce various fees can be counted as a plan to improve public relations by the bank.
Currently, JPMorgan retains a Zacks #4 Rank, which translates into a short-term Sell rating. Considering the fundamentals, we maintain our long-term Neutral recommendation on the stock.
Read the full Analyst Report on JPM
Read the full Analyst Report on USB
Read the full Analyst Report on FITB
Read the full Analyst Report on WFC
Read the full Analyst Report on BAC
Read the full Analyst Report on CBSH